Cancer specialists at the Allegheny Health Network (AHN) Esophageal and Lung Institute are recruiting patients for the first Phase III clinical trial to evaluate an immunotherapy drug, called nivolumab (Opdivo), as a potential treatment option for advanced esophageal cancer. Bristol-Myers Squibb developed nivolumab (Opdivo) and is the Sponsor of this study.
http://www.benzinga.com/pressreleases/16/08/p8326677/esophageal-lung-institute-of-the-allegheny-health-network-launches-stud
Esophageal & Lung Institute of the Allegheny Health Network Launches Study of Immunotherapy Drug For Advanced Esophageal Cancer